Polycythemia, Erythrocytosis & Clot Risk on TRT
Testosterone-Driven Red-Cell Mass, Viscosity, and the Thromboembolic/Stroke Angle
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Recognized adverse effect; managed per Endocrine Society 2018
Reference only. Not medical advice.
What can go wrong
Erythrocytosis is the most common laboratory adverse effect of TRT. The Endocrine Society 2018 guideline advises withholding testosterone when hematocrit exceeds 54% until it normalizes, then resuming at a lower dose, and lists therapeutic phlebotomy as a management option. Risk factors include injectable formulations, smoking, obstructive sleep apnea, and high altitude. Untreated, the concern is venous thromboembolism (DVT, PE) and possible contribution to arterial/arrhythmic events. Hematocrit should be checked at baseline, at 3 to 6 months, then annually.
This is something to take to a clinician. The Atlas can tell you what is known about polycythemia, erythrocytosis & clot risk on trt in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testosterone stimulates erythropoiesis, raising hemoglobin and hematocrit; in a subset of men this produces erythrocytosis (commonly defined by hematocrit above 54%). Higher hematocrit increases blood viscosity, the proposed substrate for venous thromboembolism (DVT/PE) and, by extension, arterial events. The TRAVERSE trial reported more pulmonary embolism, atrial fibrillation, and acute kidney injury on testosterone despite no excess of major adverse cardiac events. This dossier deepens the clot/stroke angle and the management algorithm.
Testosterone thickens the blood; the question is whether thicker blood clots.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Testosterone increases red-cell production by stimulating erythropoietin and by suppressing hepcidin, which increases iron availability for erythropoiesis. Hemoglobin and hematocrit rise, typically within the first months, and can exceed normal limits. Injectable testosterone, with higher peak levels, tends to raise hematocrit more than transdermal preparations. As hematocrit climbs, whole-blood viscosity increases nonlinearly; the prevailing concern is that hyperviscosity and other testosterone effects predispose to venous thromboembolism and may contribute to arterial events including stroke, though the magnitude of arterial risk remains debated.
Viscosity, VTE, and where stroke fits
The cleanest signal is venous: testosterone is associated with pulmonary embolism in multiple datasets, and TRAVERSE found more PE on testosterone (0.9% vs 0.5%). The arterial/stroke story is murkier. Older flawed observational reports and the halted TOM trial raised alarm, but TRAVERSE found no excess of major adverse cardiac events. What TRAVERSE did newly flag was more atrial fibrillation (3.5% vs 2.4%) and acute kidney injury (2.3% vs 1.5%) on testosterone. AF itself is a stroke risk factor, so the cleanest causal chain to stroke may run through arrhythmia and viscosity rather than direct atherosclerosis. The practical point: keep hematocrit controlled and watch for AF.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
- Driven by erythropoietin stimulation and hepcidin suppression
- Injectables raise hematocrit more than gels
- Withhold at hematocrit >54%, resume lower (Endocrine Society 2018)
- Therapeutic phlebotomy lowers hematocrit and viscosity
- Clearest signal is venous thromboembolism (PE)
- TRAVERSE flagged more atrial fibrillation, a stroke risk factor
Replacement is not the same as a cycle
Supraphysiological AAS can drive hematocrit far higher than replacement TRT, compounding viscosity and thrombotic risk, and users often manage it with unsupervised phlebotomy that itself risks iron-deficient, rebound erythrocytosis cycling.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Hematocrit/hemoglobin at baseline, 3-6 months, then annually
- Withhold and re-dose per the 54% threshold
- Screen for and treat obstructive sleep apnea
- Vigilance for DVT/PE symptoms and new atrial fibrillation
What people get wrong
Often saidDonating blood fully neutralizes the clot risk
ActuallyPhlebotomy lowers hematocrit and viscosity but does not address every testosterone-related thrombotic factor; it is a management tool, not a guarantee, and should be guided clinically.
Often saidHigh hematocrit on TRT is harmless if you feel fine
ActuallyErythrocytosis is asymptomatic until a thrombotic event; the 54% threshold exists precisely because the danger is silent.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Mechanism
- Erythropoietin stimulation + hepcidin suppression
- Threshold
- Hold at hematocrit >54% (Endocrine Society 2018)
- Higher with
- Injections (peak-trough) > gels; smoking, OSA, altitude
- TRAVERSE PE
- 0.9% testosterone vs 0.5% placebo
- Management
- Dose reduction, formulation change, phlebotomy
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Polycythemia, Erythrocytosis & Clot Risk on TRT. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Bhasin et al., Endocrine Society clinical practice guideline2018
Set the hematocrit >54% threshold to withhold testosterone, advised reassessment at 3-6 months then annually, and endorsed phlebotomy
Lincoff et al., TRAVERSE, NEJM2023
Testosterone noninferior for MACE but with more pulmonary embolism, atrial fibrillation, and acute kidney injury than placebo
Ohlander et al., review of testosterone and erythrocytosis2017
Summarized erythropoietin/hepcidin mechanism and formulation-dependent hematocrit rise